BioXcel Therapeutics, Inc.
BTAI
NASDAQ·Healthcare·Biotechnology·Mkt cap $5.6M
$0.18
▼ -74.76%
P/E
—
Mkt Cap
$5.6M
52-Wk Range
$0.16–$4.29
52-Week Range
$0.16 - $4.29
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 95.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary AI and machine learning algorithms for drug re-innovation
- Reduced development timelines and lower regulatory risk through repositioning approach
- First-mover advantage with FDA-approved commercial product (IGALMI)
- Highly differentiated product portfolio addressing multiple high-need therapeutic areas
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Stable outlook
Expanding IGALMI market penetration and label extensions
Value
Valuation data unavailable
Momentum
Falling
-84.5% over 3m
Quality
Strong
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying BTAI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 11, 2026
Most recent quarter reported revenue of $182.0K (+52% YoY). Reported EPS of -$0.49. Gross margin 0.0%.
Reported EPS · last 4Q
Q2 26
-$0.49
Q1 26
-$1.04
Q4 25
-$1.03
Q3 25
-$2.18
Revenue trend · last 8Q
—
—
-71%
-89%
-54%
-30%
+23%
+52%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$214.0K
$366.0K
$168.0K
$120.0K
$98.0K
$256.0K
$206.0K
$182.0K
Margins · last 8Q
Gross
0.0%
Profit
-8084.1%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Apr 2, 2026
vs Industry
How BTAI stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related